(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Metavia's earnings in 2026 is -$14,446,000.On average, 5 Wall Street analysts forecast MTVA's earnings for 2026 to be -$16,754,858, with the lowest MTVA earnings forecast at -$23,307,384, and the highest MTVA earnings forecast at -$13,143,261. On average, 5 Wall Street analysts forecast MTVA's earnings for 2027 to be -$15,948,475, with the lowest MTVA earnings forecast at -$29,118,089, and the highest MTVA earnings forecast at -$7,470,907.
In 2028, MTVA is forecast to generate -$11,154,973 in earnings, with the lowest earnings forecast at -$17,238,425 and the highest earnings forecast at -$6,087,405.